BOT - Anything but charting, page-11003

I agree that BOT is significantly undervalued, but you are comparing apples and oranges here. If you are going to compare a dermatology focused company to a radiopharma one, you might as well add a comparison to FMG as well.

What I have found is that the ASX is really just incredibly slow when it comes to healthcare stock, especially after FDA approval has actually been achieved. Seems like during the approval process the market tends to get very excited with the regular news flow and progress, but then when the company reaches the FDA approval all there is to look forward to are the 2-4 sales updates each year (and apparently these aren't as exciting and thrilling as the approval process). Eventually the sales and profits become too large to ignore, but I have found this can take the market many years sometimes. CUV is a very good example of this. That company achieved FDA approval for its dermatology related product several years ago, but the price has stagnated at a valuation of around $700m last I checked. This is despite the fact they are growing sales fast and consistently, and generate substantial amounts of cash each year (resulting in a current cash balance of $200m). Not to mention the additional pipeline products they have pending FDA approval and market release for other conditions.

However, this doesn't last forever. Plenty of examples of healthcare companies that have been around for much longer (e.g. PME, CSL, RMD, etc) that show that with time and patience, these stocks do reach their fair value. I think that punters here just need to accept the fact we may be waiting many years, and that success in the stock market requires great patience. Whilst saying that, this could also shoot to $2 tomorrow, it is impossible for anyone here to know, but I wouldn't be trying to time it that's for sure!